litlas
Log inCreate account

Diamant Thaçi

Active 2003–2025

Also published as
Diamant Thaci
178
Papers
20,112
Citations
71
h-index
166
i10-index

Citations

Citations per year for Diamant Thaçi1986: 1 citations1994: 1 citations1998: 1 citations2001: 1 citations2005: 4 citations2006: 3 citations2007: 7 citations2008: 14 citations2009: 23 citations2010: 22 citations2011: 30 citations2012: 32 citations2013: 42 citations2014: 39 citations2015: 94 citations2016: 139 citations2017: 222 citations2018: 259 citations2019: 771 citations2020: 938 citations2021: 1,036 citations2022: 912 citations2023: 993 citations2024: 1,437 citations2025: 833 citations2026: 8 citations1987–1993: no citations, so these years are not shown1995–1997: no citations, so these years are not shown1999–2000: no citations, so these years are not shown2002–2004: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,906 citing papers, 19.6% of this breakdownGermany: 888 citing papers, 9.1% of this breakdownUnited Kingdom: 656 citing papers, 6.7% of this breakdownItaly: 627 citing papers, 6.5% of this breakdownCanada: 572 citing papers, 5.9% of this breakdownChina: 504 citing papers, 5.2% of this breakdownFrance: 435 citing papers, 4.5% of this breakdownJapan: 409 citing papers, 4.2% of this breakdownSpain: 365 citing papers, 3.8% of this breakdownSwitzerland: 304 citing papers, 3.1% of this breakdownNetherlands: 303 citing papers, 3.1% of this breakdownDenmark: 263 citing papers, 2.7% of this breakdown
0%19.6%Other 25.6%

Institutions

Fields

  • Medicine56.2%
  • Immunology and Microbiology33.4%
  • Biochemistry, Genetics and Molecular Biology7.7%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Neuroscience0.5%
  • Dentistry0.3%
  • Other1.1%

Topics

  • Psoriasis: Treatment and Pathogenesis16.7%
  • Dermatology and Skin Diseases15.9%
  • Spondyloarthritis Studies and Treatments7.3%
  • Allergic Rhinitis and Sensitization5.6%
  • Asthma and respiratory diseases5.4%
  • Rheumatoid Arthritis Research and Therapies3.5%
  • Other45.6%

Coauthors

All papers

Open in search
  1. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    Authors: Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson, Kim Papp, Aileen L. Pangan, Andrew Blauvelt, Diamant Thaçi, Chia‐Yu Chu, Hyuck-Ki Hong, Norito Katoh, Amy S. Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R. Tenorio, Alvina D. Chu, Alan D. Irvine - The Lancet 2021 cited by 543

  2. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

    Authors: Jonathan I. Silverberg, Emma Guttman‐Yassky, Diamant Thaçi, Alan D. Irvine, Linda Stein Gold, Andrew Blauvelt, Eric L. Simpson, Chia‐Yu Chu, Zhuqing Liu, Renata Gontijo Lima, Sreekumar Pillai, Julien Sénéschal - New England Journal of Medicine 2023 cited by 314

  3. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

    Authors: April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, Elizabeth Colston, John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt - Journal of the American Academy of Dermatology 2022 cited by 347

  4. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

    Authors: Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, C. Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Kundu, Chitra Sekaran, Misti Linaberry, Subhashis Banerjee, Kim Papp - Journal of the American Academy of Dermatology 2022 cited by 279

  5. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

    Authors: Lisa A. Beck, Diamant Thaçi, Jennifer D. Hamilton, Neil M.H. Graham, Thomas Bieber, Ross E. Rocklin, Jeffrey E. Ming, Haobo Ren, Richard Kao, Eric L. Simpson, Marius Ardeleanu, Steven P. Weinstein, Gianluca Pirozzi, Emma Guttman‐Yassky, Mayte Suárez‐Fariñas, Melissa Hager, Neil Stahl, George D. Yancopoulos, Allen Radin - New England Journal of Medicine 2014 cited by 1,405

  6. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

    Authors: Thomas Bieber, Eric L. Simpson, Jonathan I. Silverberg, Diamant Thaçi, C. Paul, Andrew Pink, Yoko Kataoka, Chia‐Yu Chu, Marco DiBonaventura, Ricardo Rojo, Jeremias Antinew, Ileana A. Ionita, Rodney Sinclair, Seth Forman, Jacek Zdybski, Pinaki Biswas, Bimal Malhotra, Fan Zhang, Hernán Valdez - New England Journal of Medicine 2021 cited by 453

  7. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

    Authors: Amy S. Paller, Elaine C. Siegfried, Diamant Thaçi, Andreas Wollenberg, Michael J. Cork, Peter D. Arkwright, Melinda Gooderham, Lisa A. Beck, Mark Boguniewicz, Lawrence Sher, Jamie Weisman, John T. O’Malley, Naimish Patel, Megan Hardin, Neil M.H. Graham, Marcella Ruddy, Xian Sun, John D. Davis, Mohamed Kamal, Faisal A. Khokhar, David M. Weinreich, George D. Yancopoulos, Bethany Beazley, Ashish Bansal, Brad Shumel - Journal of the American Academy of Dermatology 2020 cited by 389

  8. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Authors: Kristian Reich, Kim Papp, Andrew Blauvelt, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, N. Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B. Kimball - The Lancet 2017 cited by 556

  9. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease

    Authors: Marcus Harbord, Vito Annese, Stephan R. Vavricka, Matthieu Allez, Manuel Barreiro‐de Acosta, Kirsten Muri Boberg, Johan Burisch, Martine De Vos, Annemarie de Vries, Andrew D. Dick, Pascal Juillerat, Tom H. Karlsen, Ioannis E. Κoutroubakis, Péter L. Lakatos, Tim Orchard, Pavol Papay, Tim Raine, Max Reinshagen, Diamant Thaçi, Herbert Tilg, Franck Carbonnel - Journal of Crohn s and Colitis 2015 cited by 808

  10. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

    Authors: Marjolein de Bruin‐Weller, Diamant Thaçi, Catherine Smith, Kristian Reich, Michael J. Cork, Allen Radin, Q. Zhang, Bolanle Akinlade, A. Gadkari, Laurent Eckert, Thomas Hultsch, Z. Chen, Gianluca Pirozzi, Neil M.H. Graham, Brad Shumel - British Journal of Dermatology 2017 cited by 475

  11. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

    Authors: Kim Papp, Kenneth B. Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab Girgis, Sudeep Kundu, Subhashis Banerjee - New England Journal of Medicine 2018 cited by 414

  12. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

    Authors: Emma Guttman‐Yassky, Diamant Thaçi, Aileen L. Pangan, Hwanhee Hong, Kim Papp, Kristian Reich, Lisa A. Beck, Mohamed‐Eslam F. Mohamed, Ahmed A. Othman, J. Anderson, Yihua Gu, Henrique D. Teixeira, Jonathan I. Silverberg - Journal of Allergy and Clinical Immunology 2019 cited by 357

  13. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

    Authors: Joseph F. Merola, Robert Landewé, Iain B. McInnes, Philip J. Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D. Gladman, Laure Gossec, Alice B. Gottlieb, Diamant Thaçi, Richard B. Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates - The Lancet 2022 cited by 158

  14. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

    Authors: Mette Deleuran, Diamant Thaçi, Lisa A. Beck, Marjolein de Bruin‐Weller, Andrew Blauvelt, Seth Forman, Robert Bissonnette, Kristian Reich, Weily Soong, Iftikhar Hussaın, Peter Foley, Michihiro Hide, Jean‐David Bouaziz, Joel M. Gelfand, Lawrence Sher, Marie L. A. Schuttelaar, Chen Wang, Zhen Chen, Bolanle Akinlade, Abhijit Gadkari, Laurent Eckert, John D. Davis, Manoj Rajadhyaksha, Heribert Staudinger, Neil M.H. Graham, Gianluca Pirozzi, Marius Ardeleanu - Journal of the American Academy of Dermatology 2019 cited by 256

  15. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial

    Authors: Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi, Lori Ann Cox, Anindita Banerjee, George Han, Iltefat Hamzavi, Anand K. Ganesan, Mauro Picardo, Diamant Thaçi, John E. Harris, Jung Min Bae, Katsuhiko Tsukamoto, Rodney Sinclair, Amit G. Pandya, Abigail Sloan, Dahong Yu, Kavita Gandhi, Michael S. Vincent, Brett King - Journal of the American Academy of Dermatology 2022 cited by 146

  16. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

    Authors: Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey Crowley, Caitriona Ryan, James G. Krueger, Tsen‐Fang Tsai, Mary Flack, Yihua Gu, David Williams, Elizabeth H. Thompson, C. Paul - The Lancet 2019 cited by 298

  17. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

    Authors: Margitta Worm, Eric L. Simpson, Diamant Thaçi, Robert Bissonnette, J.‐P. Lacour, Stefan Beissert, Makoto Kawashima, Carlos Ferrándiz, Catherine Smith, Lisa A. Beck, Kuo‐Chen Chan, Zhen Chen, Bolanle Akinlade, Thomas Hultsch, Heribert Staudinger, Abhijit Gadkari, Laurent Eckert, John D. Davis, Manoj Rajadhyaksha, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Marius Ardeleanu - JAMA Dermatology 2019 cited by 206

  18. Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases

    Authors: Hideyuki Ujiie, David Rosmarin, Michael P. Schön, Sonja Ständer, Katharina Boch, Martin Metz, Marcus Maurer, Diamant Thaçi, Enno Schmidt, Connor Cole, Kyle T. Amber, Dario Didona, Michael Hertl, Andreas Recke, Hanna Graßhoff, Alexander Hackel, Anja Schümann, Gabriela Riemekasten, Katja Bieber, Gant Sprow, Joshua Dan, Detlef Zillikens, Tanya Sezin, Angela M. Christiano, Kerstin Wolk, Robert Sabat, Khalaf Kridin, Victoria P. Werth, Ralf J. Ludwig - Frontiers in Medicine 2022 cited by 150

  19. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks

    Authors: Esther von Stebut, Kristian Reich, Diamant Thaçi, Wolfgang Köenig, Andreas Pinter, Andreas Körber, Tienush Rassaf, Ari Waisman, Venkatesh Mani, Denise P. Yates, Jennifer Frueh, Christian Sieder, Nima Melzer, Nehal N. Mehta, Tommaso Gori - Journal of Investigative Dermatology 2018 cited by 223

  20. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

    Authors: Akimichi Morita, Bruce Strober, A. David Burden, Siew Eng Choon, Milan J. Anadkat, Slaheddine Marrakchi, Tsen‐Fang Tsai, Kenneth B. Gordon, Diamant Thaçi, Min Zheng, Na Hu, Thomas Haeufel, Christian Thoma, Mark Lebwohl - The Lancet 2023 cited by 110

  21. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

    Authors: Diamant Thaçi, Eric L. Simpson, Lisa A. Beck, Thomas Bieber, Andrew Blauvelt, Kim Papp, Weily Soong, Margitta Worm, Jacek C. Szepietowski, Howard Sofen, Makoto Kawashima, Richard Wu, Steven P. Weinstein, Neil M.H. Graham, Gianluca Pirozzi, Ariel Teper, E. Rand Sutherland, Vera Mastey, Neil Stahl, George D. Yancopoulos, Marius Ardeleanu - The Lancet 2015 cited by 566

  22. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)

    Authors: Diamant Thaçi, Eric L. Simpson, Mette Deleuran, Yoko Kataoka, Zhen Chen, Abhijit Gadkari, Laurent Eckert, Bolanle Akinlade, Neil M.H. Graham, Gianluca Pirozzi, Marius Ardeleanu - Journal of Dermatological Science 2019 cited by 185

  23. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

    Authors: Kim Papp, Alan Menter, Mai Abe, Boni E. Elewski, Steven R. Feldman, Alice B. Gottlieb, Richard G. Langley, Thomas A. Luger, Diamant Thaçi, M. Buonanno, Pankaj Gupta, James Proulx, Shu-Ping Lan, Robert Wołk, the OPT Pivotal 1 and OPT Pivotal 2 investigators - British Journal of Dermatology 2015 cited by 322

  24. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

    Authors: Kim Papp, Kristian Reich, C. Paul, Andrew Blauvelt, Wojciech Baran, Chantal Bolduc, D. Toth, Richard G. Langley, Jennifer Clay Cather, Alice B. Gottlieb, Diamant Thaçi, James G. Krueger, Chris B. Russell, C.E. Milmont, Jing Li, Paul Klekotka, Greg Kricorian, Ajay Nirula - British Journal of Dermatology 2016 cited by 459